Peptide Comparison
Cardiogen vs Pancragen
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Cardiogen and Pancragen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Cardiogen | Pancragen | |
|---|---|---|
| Class | Khavinson short peptide bioregulator | Khavinson short peptide bioregulator |
| Drug class | Tissue Repair | Metabolic & Weight |
| Mechanism | Tissue-specific gene expression modulation in cardiomyocytes | Tissue-specific gene expression in pancreatic beta-cells |
| Route | Oral | Oral |
| Half-life | Short (minutes) | Short (minutes) |
| Dosage (research) | Oral capsule 1-2x daily | Oral capsule 1-2x daily |
| Evidence tier | Russian Research | Russian Research |
| Research depth | 11 indexed | 8 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western evidence; no regulatory approval | Sparse controlled trials |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Cardiogen or Pancragen?
Cardiogen and Pancragen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Cardiogen and Pancragen?
Cardiogen is classed as Khavinson short peptide bioregulator; Pancragen is classed as Khavinson short peptide bioregulator. Reported mechanism: Cardiogen, Tissue-specific gene expression modulation in cardiomyocytes; Pancragen, Tissue-specific gene expression in pancreatic beta-cells. Reported half-life: Cardiogen, Short (minutes); Pancragen, Short (minutes). Routes in published studies: Cardiogen, Oral; Pancragen, Oral.
Which has stronger evidence, Cardiogen or Pancragen?
Cardiogen and Pancragen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Cardiogen is graded Russian Research, with 2 cited sources on its reference page and 11 indexed studies. Pancragen is graded Russian Research, with 2 cited sources on its reference page and 8 indexed studies.
Which is more accessible, Cardiogen or Pancragen?
Neither Cardiogen nor Pancragen is an FDA-approved drug. Catalog status: Cardiogen, Research; Pancragen, Research.
Are Cardiogen and Pancragen ever combined?
Cardiogen and Pancragen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…